Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02573220
Title Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors University of Chicago

colorectal cancer


Cetuximab + Fluorouracil + Irinotecan + Leucovorin

Age Groups: adult
Covered Countries ITA

Additional content available in CKB BOOST